Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950353 | 0.84 | HDAC6 (0.35) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL3311643 | 0.76 | TDP1 (0.47) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL4693101 | 0.75 | HDAC6 (0.39) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL111602 | 0.75 | CA14 (0.40) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL499275 | 0.73 | HDAC6 (0.38) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL5765810 | 0.72 | HDAC6 (0.37) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL20421829 | 0.72 | CTSK (0.33) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL22814762 | 0.70 | HDAC6 (0.39) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL1462541 | 0.70 | CA14 (0.37) | HDAC6CTSKCA14HDAC1HDAC2 | |
| SCHEMBL7106544 | 0.70 | HDAC6 (0.36) | HDAC6CTSKCA14HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| CN-118159540-A | Novel capsid assembly inhibitor | 南韩商AM科学股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2020-06-30 | — | — | US | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| EP-2857401-B1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| EP-2855488-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | Ares Trading SA (CH) | 2015-04-08 | — | — | EP | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8969570-B2 | Beta-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150038478-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-02-05 | — | — | US | disclosed |
| US-20140316133-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-10-23 | — | — | US | disclosed |
| WO-2013182274-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | ARES TRADING S.A. (CH) | 2013-12-12 | — | — | WO | disclosed |
| EP-2671885-A1 | Imidazo-oxadiazole and Imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20130296555-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | HDAC6 2685/4885CTSK 2619/4885CA14 3250/4885 |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | HDAC6 2685/4885CTSK 2619/4885CA14 3250/4885 |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | HDAC6 544/4885CTSK 697/4885CA14 4823/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | HDAC6 2685/4885CTSK 2619/4885CA14 3250/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | HDAC6 2685/4885CTSK 2619/4885CA14 3250/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | HDAC6 2685/4885CTSK 2619/4885CA14 3250/4885 |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | APP, BACE1, PSEN1 | HDAC6 286/4885CTSK 3866/4885CA14 4583/4885 |
| US-20140316133-A1 | BETA-LACTAMASE INHIBITORS | DDO, CMBL, BBOX1 | HDAC6 1421/4885CTSK 981/4885CA14 4698/4885 |
| US-20150038478-A1 | BETA-LACTAMASE INHIBITORS | DDO, CMBL, BBOX1 | HDAC6 1583/4885CTSK 1111/4885CA14 4680/4885 |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | HDAC6 2685/4885CTSK 2619/4885CA14 3250/4885 |
| US-20130296555-A1 | BETA-LACTAMASE INHIBITORS | DDO, CMBL, BBOX1 | HDAC6 1583/4885CTSK 1111/4885CA14 4680/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | HDAC6 2685/4885CTSK 2619/4885CA14 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.